Publication date: Jun 07, 2025
Oncology patients may require long-term treatment adherence and may face additional challenges to adherence during national crises. This study investigated changes in treatment adherence among breast cancer patients before and during the COVID-19 pandemic. A historical prospective study was conducted using electronic medical records of adult breast cancer patients in the post-acute treatment phase; those receiving preventive oral monotherapy were analyzed. Adherence was assessed using the proportion of days covered (PDC). The pre-pandemic baseline PDC among 4274 patients was 78. 5%. During the four COVID-19 waves (Feb 2020-Oct 2021), patients with low pre-pandemic adherence (PDC
Open Access PDF
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 pandemic |
| disease | MESH | breast cancer |
| pathway | KEGG | Breast cancer |
| disease | MESH | chronic illness |
| drug | DRUGBANK | Trestolone |
| disease | MESH | shock |
| disease | MESH | anxiety |
| disease | IDO | country |
| drug | DRUGBANK | Coenzyme M |
| disease | MESH | psychological distress |
| drug | DRUGBANK | Indoleacetic acid |
| disease | MESH | tuberculosis |
| pathway | KEGG | Tuberculosis |
| pathway | REACTOME | Reproduction |
| drug | DRUGBANK | Phenylpropanolamine |
| disease | IDO | intervention |
| disease | MESH | coronary artery disease |
| disease | MESH | severe mental disorders |
| drug | DRUGBANK | Capecitabine |
Original Article
(Visited 1 times, 1 visits today)